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Abstract
Background: Molecular intratumour heterogeneity (ITH) is common in clear cell renal carcinomas (ccRCCs). However, it
remains unknown whether this is mirrored by heterogeneity of drug responses between metastases in the same patient.
Methods: We performed a retrospective central radiological analysis of patients with treatment-naïve metastatic ccRCC
receiving anti-angiogenic tyrosine kinase inhibitors (TKIs) (sunitinib or pazopanib) within three similar phase II trials.
Treatment was briefly interrupted for cytoreductive nephrectomy. All patients had multiple metastases that were measured
by regular computed tomography scans from baseline until Response Evaluation Criteria In Solid Tumours (RECIST)-defined
progression. Each metastasis was categorised as responding, stable or progressing. Patients were classed as having a
homogeneous response if all lesions were of the same response category and a heterogeneous response if they differed.
Results: A total of 115 metastases were assessed longitudinally in 27 patients. Of these patients, 56% had a heterogeneous
response. Progression occurred through the appearance of new metastases in 67%, through progression of existing lesions
in 11% and by both in 22% of patients. Despite RECIST-defined progression, 57% of existing metastases remained
controlled. The sum of controlled lesions was greater than that of uncontrolled lesions in 47% of patients who progressed
only with measurable new lesions.
Conclusions: We identified frequent ITH of anti-angiogenic TKI responses, with subsets of metastases responding and
progressing within individual patients. This mirrors molecular ITH and may indicate that anti-angiogenic drug resistance is
confined to subclones and not encoded on the trunk of the tumours’ phylogenetic trees. This is clinically important, as
patients with small-volume progression may benefit from drug continuation. Predominant progression with new rather
than in existing metastases supports a change in disease biology through anti-angiogenics. The results highlight limitations
of RECIST in heterogeneous cancers, which may influence clinical trial data validity. This analysis requires prospective
confirmation.
Trial registration: European Clinical Trials Database(EudraCT): 2009-016675-29, registered 17 March 2010;
EudraCT: 2006-004511-21, registered 09 March 2007; EudraCT: 2006-006491-38, registered 22 December 2006.
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Background
Extensive genetic, transcriptomic, signalling pathway activ-
ity and predictive and prognostic biomarker heterogeneity
have been shown within and between clear cell renal car-
cinoma (ccRCC) primary tumours and metastases [1–4].
Yet, it has not been investigated whether this molecular
intratumour heterogeneity (ITH) is mirrored by heteroge-
neous response and progression patterns of different metas-
tases within individual patients during anti-angiogenic
tyrosine kinase inhibitor (TKI) treatment, which is standard
of care in the first- and second-line treatment of metastatic
ccRCCs [5–7]. This information is clinically relevant, as
uniform responses of multiple metastatic sites would sug-
gest that drug sensitivity or resistance is determined by a
common molecular characteristic encoded on the trunk of
the tumour’s phylogenetic tree [8]. In contrast, frequent
occurrence of heterogeneity may hinder development of
predictive biomarkers to identify patients likely to benefit
from these treatments. Heterogeneous progression patterns
may also complicate clinical decisions. If small-volume pro-
gression is common despite ongoing control of the disease
bulk, systemic therapy continuation or local treatment
modalities could be offered and biopsy approaches to iden-
tify drug-resistant subclones could be informative, whereas
progression in all or most metastases may require a switch
to a different class of systemic treatment.
Methods
Patients and treatment
Patients with treatment-naïve metastatic ccRCC enrolled in
three similar single-arm phase II studies of first-line pazopa-
nib (study A: PANTHER) or sunitinib (study B: SuMR,
study C: N06SUN) [9–12] and interval nephrectomy were
eligible for inclusion into this post hoc radiological substudy.
All trials were approved by an ethics committee and entered
in a clinical trials register (A: EudraCT 2009-016675-29, B:
EudraCT 2006-004511-21, C: EudraCT 2006-006491-38).
All patients provided signed written informed consent. Suni-
tinib (50 mg PO once daily for 4 weeks, 2 weeks off drug)
was administered for two (study C) or three cycles (study B)
and pazopanib (800 mg PO once daily) was administered
for 12–16 weeks prior to planned cytoreductive nephrec-
tomy. Drug therapy was restarted following recovery from
surgery until radiological disease progression.
Data were available from 98 patients included in a prior
interim analysis of these three trials [12]. To assess progres-
sion patterns, only patients with Response Evaluation
Criteria In Solid Tumours (RECIST) 1.1-defined disease
progression by the data-freeze time point (01 May 2014)
were eligible for assessment (n = 60) (Fig. 1). Patients who
underwent nephrectomy were required to have restarted
the drug after surgery to be included for analysis. For six
patients who restarted treatment but had progressed during
the planned drug-free interval peri-nephrectomy, the post-
nephrectomy scan was used as baseline to avoid biases that
may result from interval progression. Further, patients who
had unplanned treatment breaks >21 days were excluded
(n = 8), as interval progression was likely in those cases.
These criteria resulted in 27 patients being eligible for
assessment in the final analysis of whole body computed
tomography (CT) or positron emission tomography (PET)-
CT imaging of two or more measurable lesions.
Disease assessment
CT or PET-CT scans of at least the chest and abdomen
were performed according to trial protocols at baseline,
before and after surgery, and at 3- month intervals there-
after until disease progression or if clinically indicated. CT
scans or CT components of PET-CT scans were re-
analysed centrally within the lead centre of each trial by
two radiologists (studies A/B: YT, study C: WP) according
to modified RECIST 1.1 criteria. The primary renal lesion
was excluded from the analysis as this was removed surgi-
cally in all patients except 11, who did not undergo sur-
gery due to progression before scheduled nephrectomy or
patient choice. All measurable metastases at baseline were
included for response pattern assessments (i.e. more than
five lesions in total), including lung nodules between 5–
10 mm if unequivocally considered metastatic. Unidimen-
sional measurements were performed to the nearest milli-
metre with picture archiving and communication system
(PACS) software on all scans from baseline to progression.
Statistical analysis
A Fisher’s exact test was used to test the association be-
tween lesion response category and lesion size and between
progression pattern and treatment type. A proportion test
was used to compare the heterogeneous response type for
pazopanib- and sunitinib-treated patients. Intercooled Stata
13 (Stata Corporation, College Station, TX, USA) was used
for the statistical analysis. A p value of less than 0.05 was
considered significant.
Results
Patients and radiological assessment
Ninety-eight patients with metastatic ccRCC scheduled
for cytoreductive nephrectomy were included into one of
three similar phase II trials of peri-operative therapy with
sunitinib or pazopanib. Twenty-seven patients fulfilled the
inclusion criteria for this radiological subanalysis (Fig. 1).
Characteristics of this subgroup were similar to those of
all patients included into the trials (Table 1), indicating
that the selection criteria for this subanalysis did not
introduce major known biases.
All measurable lesions were followed on regular CT
scans until RECIST-defined progression (Additional file
1: Table S1). In order to assess intraobserver variability,
20% of all patients (n = 5) were chosen randomly for a
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re-analysis by the same radiologist blinded to previous
measurements. The Pearson correlation coefficient of
0.99 indicated highly reproducible measurements.
Heterogeneity at best response
We first assessed whether multiple metastatic sites within
individual patients responded similarly to the drug or
whether heterogeneous radiological responses occurred.
Larger lesions may take longer to respond than smaller
lesions; thus, each metastasis was categorised based on the
best response achieved over the treatment period to
mitigate the impact of such response dynamics. We identi-
fied the minimal diameter of each of 115 measurable metas-
tases during drug therapy and compared it to the diameter
of the same lesion at baseline (Additional file 1: Table S1).
Based on the relative size change, each metastasis was
classified into one of three RECIST-analogous response
categories: Responding Lesions (RLs) decreased in size by
30% or more compared to baseline, Progressing Lesions
(PLs) increased in size by 20% or more and all other lesions
were classified as Stable Lesions (SLs) (example in Fig. 2;
Additional file 2: Figure S1).
Fig. 1 Flowchart of patient selection for radiological heterogeneity analysis. PD progressive disease
Table 1 Patient characteristics
Characteristic Overall cohort [12] Heterogeneity study
Number of patients 98 27
Male patients (n, %) 75 (77%) 23 (85%)
Median age (years) 59 (range 37–78) 59 (range 34–73)
MSK risk group Intermediate 70 (71%) 18 (67%)
Poor 28 (29%) 9 (33%)
Nephrectomy Yes 62 (63%) 16 (59%)
Organ sites affected by metastases 1 30 (31%) 8 (30%)
2 39 (40%) 13 (48%)
3+ 29 (29%) 6 (22%)
MSK Memorial Sloan Kettering [22]
Characteristics of all 98 patients included into the three phase II trials compared to those of the 27 patients in the radiological heterogeneity substudy
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Each patient was assigned either to the group with homo-
geneous drug responses (all lesions within the same re-
sponse category) or heterogeneous responses (lesions in at
least two of the three response categories). Fifteen patients
(55.6%) showed a heterogeneous response and 12 patients
(44.4%) a homogeneous response (Fig. 3, Additional file 3:
Table S2). In 8 patients (29.6%), at least one metastasis
showed outright progression (PL), while others were stable
or responded. Heterogeneous responses were more fre-
quent in patients treated with pazopanib (7/8 = 88%) than
sunitinib (8/19 = 44%) (p = 0.03), but did not differ in
patients who had dose reductions due to toxicities (5/9 =
56%) compared to those who did not (10/18 = 56%). The
response patterns were similar and there was no statistically
significant difference for patients who underwent nephrec-
tomy (8/16 = 50% heterogeneous responses) and those who
did not have a nephrectomy (7/11 = 64% heterogeneous re-
sponses, p = 0.70). Thus, heterogeneous responses cannot
be explained by suboptimal dosing or nephrectomy.
In addition to the analysis based on best response per
lesion, we also evaluated response heterogeneity by com-
paring lesion sizes at baseline with the scan showing the
best overall response to treatment (lowest observed sum of
all measurable lesion diameters). This approach, which is
more similar to radiological practice, found heterogeneous
responses in a similar fraction of patients (63%) (Fig. 3).
Metastases were catergorised as small (≤2 cm, n = 55),
intermediate (>2–4 cm, n = 39) and large lesions (>4 cm,
n = 21) to assess how the size on baseline scan relates to
the best response achieved. Large lesions were signifi-
cantly more stable compared to smaller and intermedi-
ate lesions together (p = 0.03) (Fig. 4). This may result
from large fibrotic or necrotic components that may not
change during therapy. Alternatively, the change of
tumour volume which is necessary before a 20% increase
or 30% decrease in diameter is detected may not be
achievable for many large lesions within the treatment
period [13]. However, 82% (94/115) of metastases were
of small or intermediate size. After removing lesions
measuring >4 cm from the analysis, 57% (13/23) of pa-
tients with at least two measurable metastases remaining
still showed a heterogeneous response. Thus, the pres-
ence of large lesions is not the main driver of response
heterogeneity.
This analysis demonstrates that heterogeneous responses
with lesions in two or three different response categories
are common in ccRCC. Thus, individual lesions can differ
with respect to drug sensitivity, suggesting the molecular
determinants of drug response are unlikely to be encoded
on the trunk of these tumours’ phylogenetic trees.
Heterogeneity at progression
The analysis of drug resistance heterogeneity at RECIST-
defined cancer progression was the next aim. Each me-
tastasis was categorised as described into RL/SL/PL
based on the diameter at progression compared to base-
line; however, lesions that increased ≥20% compared to
nadir were also labelled PL (Additional file 1: Table S1
and Additional file 4: Figure S2). Measurable and non-
measurable new lesions (NLs) were also recorded. Only
3/27 patients (11%) had progression solely based on an
increase in the sum of target lesions of ≥20% (example
in Fig. 5a). Six patients (22%) showed progression
through NL and a simultaneous increase in the sum of
target lesions ≥20% (example in Fig. 5b), whereas NL
alone defined progression in the remaining 18 patients
(67%) (example in Fig. 5c). In 7 of these 18 patients, all
21 metastases that had already been present on the base-
line scan were still classed as SL or RL at progression.
No statistically significant difference in progression pat-
tern was seen between patients treated with pazopanib
compared to sunitinib (p = 0.68). As per RECIST criteria,
Fig. 2 Example of individual lesion response assessments within one patient. Lesion size on each CT scan relative to the size on the baseline scan was
calculated until RECIST-defined progression. Based on the best response that was achieved over the treatment period, each lesion was categorised
either as a Responding Lesion (RL, 30% or greater decrease in diameter compared to baseline), Progressing Lesion (PL, 20% or greater increase in
diameter compared to baseline) or Stable Lesion (SL, all remaining lesions). The emergence of new lesions (NL) was also recorded
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the occurrence of any new malignant lesion defines pro-
gression, irrespective of its absolute size or the relative
size in comparison to that of target lesions present from
baseline. Thus, in cancers in which progression is predom-
inantly driven by the occurrence of new lesions, RECIST
criteria may frequently lead to treatment discontinuation
while the bulk of the disease remains controlled. Indeed, the
sum of controlled lesions (RLs and SLs) was greater than
that of uncontrolled lesions (PLs and NLs) in 7/15 patients
(47%) who progressed only with measurable new lesions
(Fig. 6). Overall, 66/115 baseline metastases (57%) assessed
at progression remained stable or were still responding at
RECIST-defined progression, further supporting this notion.
This may be consistent with the evolution of drug-resistant
clones in a subset of metastases, whereas the majority of
metastases may remain drug-sensitive.
Discussion
This small study of 27 out of 98 patients who fulfilled the
criteria for a radiological re-analysis demonstrates fre-
quent anti-angiogenic drug response heterogeneity be-
tween ccRCC metastases both during early treatment and
at progression. Due to the risks and technical difficulties
of biopsying multiple metastatic sites, tissues for correla-
tive molecular analyses were not available. However, the
observed phenotypic heterogeneity during drug therapy
resembles the genotypic and transcriptomic heterogeneity
a
b
Fig. 3 Venn diagram of response patterns. Percentage of 27 patients
with the indicated combination of lesion response categories based
on a the assessment of the best response achieved per lesion and b
assessment on the specific scan showing the best overall response.
RL Responding Lesion, SL Stable Lesion, PL Progressing Lesion
Fig. 4 Best achieved response by baseline lesion size. Best response
achieved by each individual lesion compared to its size at baseline.
p value refers to SLs compared to RLs and PLs in ≤4 cm lesions
versus >4 cm lesions. RL Responding Lesion, SL Stable Lesion, PL
Progressing Lesion
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previously described in ccRCC [1–4]. Hence, it is conceiv-
able that molecular alterations that determine treatment
responses are unlikely to be encoded by early mutations,
called truncal mutations, and that subclonal heterogeneity
is a key driver of this intrapatient response heterogeneity.
The variable drug responses of different ccRCC metasta-
ses further indicate that single biopsies will most likely be
insufficient to identify patients who will progress early.
Circulating tumour DNA sequencing, which may sample
multiple metastatic sites simultaneously through the
perfusing blood [14], or functional imaging that can detect
individual drug-resistant metastases [15, 16] may be more
suitable to identify such individuals.
Regardless of the underlying molecular mechanisms, our
finding that drug sensitivity phenotypes often differ between
metastases within patients adds to the challenges arising
from ITH for precision cancer medicine [17]. Radiological
response assessments based on RECIST criteria are com-
monly applied for treatment decision making in metastatic
cancers. Yet, the impact of ITH on reliable determination of
decisions to discontinue or switch to alternative therapy has
not been thoroughly assessed. A pertinent finding was the
large proportion of patients in whom a relatively small
fraction of the entire disease bulk progressed whereas the re-
mainder remained controlled. As pazopanib/sunitinib treat-
ment was stopped at radiological progression, we could not
investigate whether further metastases would start to pro-
gress soon if treatment had continued beyond progression.
Nevertheless, this raises the possibility that pazopanib/suni-




Fig. 5 Patterns at progression. Examples of RECIST progression patterns. a ≥20% increase in size of existing disease from nadir defining progression. b New
lesions and ≥20% increase in size of existing disease from nadir defining progression. c New lesions only defining progressive disease (R right, L left, green
line responding lesion at progression, blue line stable lesion at progression, red line progressing lesion at progression, measurements as per size at baseline)
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therapies for small-volume drug-resistant disease, may lead
to better outcomes than immediate stopping or switching to
second-line therapy. To date, robust radiological tools and
criteria to assess ITH have not been defined. Imaging ap-
proaches which can assess the fraction of the cancer load
that is progressing within a patient, for example, through
volumetric analysis, may be desirable to guide such
decisions. Novel imaging approaches, such as CT texture
analysis, functional MRI and other functional imaging mo-
dalities, could further assist in the detection of metastases
that differ in their biological characteristics. Some of these
technologies have already been shown to correlate with out-
comes in cancer patients, including those with ccRCC [18].
The large proportion of cancers that progressed through
new lesions alone (67%) may also influence clinical trial
data interpretation and validity. The following example il-
lustrates this: a small new lesion defines progression based
on RECIST criteria even if several large lesions remain con-
trolled. If such a patient enters a subsequent clinical trial
using RECIST criteria for progression-free survival (PFS)
assessment, the new lesion will be counted towards the
diameter of all target lesions. Assuming the patient is
treated with a drug with identical or similar efficacy and
mechanism of action as used first line, the bulk of the
cancer which has remained sensitive throughout will be
controlled again and the contribution of the small drug-
resistant lesion to the overall target lesion diameter is small.
Hence, even if the new drug has identical activity to the
one used during first-line therapy, the patient is likely to
achieve a substantial increase in PFS compared to that
achieved without treatment or with a less active drug. This
highlights a potential limitation of RECIST in cancer types
progressing predominantly with new lesions, and this is
particularly relevant in ccRCC where anti-angiogenic agents
with similar mechanisms have been assessed sequentially.
For example, the phase III AXIS trial that reported a PFS
gain from axitinib compared to the less potent sorafenib
may be affected by such effects [19, 20]. The analysis of
progression patterns when these patients failed first-line
therapy could shed light on this subject. Whether similar
benefit would be achieved by continuation of first-line anti-
angiogenics is an important question.
Previous analyses of progression patterns in patients with
metastatic ccRCC receiving the anti-angiogenic drugs beva-
cizumab or sorafenib found that new metastases alone and
new metastases combined with an increase of existing
disease defined disease progression in 18% and 10% of
patients, respectively [21]. The higher proportion of new
lesions in our study may reflect differences in tumour char-
acteristics between the studies. All patients in our trials had
presented with synchronous metastases, a feature of more
aggressive ccRCCs [22]. Alternatively, the increased anti-
angiogenic potency of sunitinib and pazopanib compared to
sorafenib/bevacizumab may alter dissemination and recur-
rence patterns [23]. This has previously been suggested by
studies showing anti-angiogenic agents to promote cancer
invasiveness and dissemination in mouse models [24, 25]. A
subsequent post hoc analysis of the phase III trial comparing
sunitinib with interferon-α concluded that sunitinib did not
alter tumour biology [26]. However, this analysis did not
specifically assess the overall patterns of disease progression
or the occurrence of new metastatic sites. Thus, although a
survival benefit of targeted therapy has clearly been shown
[27], these results warrant further investigation into the
impact of anti-angiogenic TKIs on the biology and evolution
of metastatic ccRCC.
Our study demonstrated heterogeneity of response and
progression patterns on anti-angiogenic therapy. However,
it is limited by the design of the phase II trials analysed.
These were enriched for high-risk patients, and 16 patients
underwent an interval nephrectomy which required a brief
peri-operative treatment interruption (median 35 days,
range 18–71 days). Based on the aims of this study, the ana-
lysis had to be restricted to patients with two or more as-
sessable metastatic lesions who had progressed during
ongoing anti-angiogenic therapy. Only 27 patients met
these criteria and were included into the final analysis
(Fig. 1). This small patient number could create potential
biases, and the original studies were not powered for this
retrospective analysis. Thus, our findings need confirmation
Fig. 6 Controlled versus uncontrolled lesions in patients progressing
with measurable new lesions only. The sum of diameters of controlled
lesions (responding and stable lesions combined) and the sum of
diameters of uncontrolled lesions (progressing and new lesions
combined) is shown relative to the sum of all lesion diameters for 15
patients in whom only measurable new lesions defined progression
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in ideally prospective analyses of larger patient numbers to
confirm results, and suitable data should be collected
routinely in the context of large registration trials.
Conclusions
Our results demonstrate phenotypic heterogeneity of anti-
angiogenic TKI responses and resistance in patients with
metastatic ccRCC. We hypothesise that these findings
may be driven by the molecular ITH previously demon-
strated in ccRCC. Although future confirmation of these
results is required, this study clearly outlines some of the
challenges arising from ITH for clinical trial interpretation
and for clinical decision making. Incorporating response
and resistance heterogeneity assessments in clinical prac-
tice may increase patient benefit in the future.
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